科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Haemophilia : the official journal of the World Federation of Hemophilia2026-08-26

Five-Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study.

Azusa Nagao, Akihiro Sawada, Takeshi Kanematsu, Naoya Yamasaki, Hideyuki Takedani, Masanori Nojima, Yukio Hiroi, Teruhisa Fujii, Nobuaki Suzuki, Tadashi Matsushita, Satoshi Higasa, Kagehiro Amano, Yushi Chikasawa

一句话结论 · In one sentence

Over 5 years, treatment strategies in adults with haemophilia A shifted towards EHL and nonfactor therapies, with reduced injection frequency among severe haemophilia A receiving prophylaxis. Bleeding rates remained stable and target joints modestly decreased, suggesting that bleeding outcomes alone may not fully reflect the evolving clinical burden in aging adults with haemophilia.

原始摘要(英文原文)· Original abstract
BACKGROUND: Prophylactic treatment for haemophilia has evolved with the introduction of extended half-life (EHL) and nonfactor products. However, long-term real-world data describing how these advances have affected adults with haemophilia remain limited. OBJECTIVES: To evaluate 5-year changes in treatment strategies and clinical outcomes in adults aged ≥40 years with haemophilia. METHODS: We analyzed 5-year longitudinal data from ADVANCE Japan, a nationwide prospective registry of adults aged ≥40 years with haemophilia. RESULTS: Of approximately 600 registered participants, 568 inhibitor-negative individuals were included in this analysis. The median follow-up duration was 4.99 years (Q1-Q3, 4.89-5.92). In haemophilia A, treatment strategies shifted towards EHL and nonfactor therapies over time. Among participants with severe haemophilia A receiving prophylaxis, median injection frequency decreased from 2.0 to 1.0 injection per week over 5 years (p < 0.001). In contrast, among participants with severe haemophilia B, injection frequency remained unchanged (p = 0.563). Despite these therapeutic transitions, annualized bleeding rate (ABR) and annualized joint bleeding rate (AjBR) showed no significant longitudinal changes across age groups in either haemophilia A or B. The proportion of participants with at least one target joint decreased from 88/568 (15.5%) at baseline to 72/548 (13.1%) in 2024. CONCLUSIONS: Over 5 years, treatment strategies in adults with haemophilia A shifted towards EHL and nonfactor therapies, with reduced injection frequency among severe haemophilia A receiving prophylaxis. Bleeding rates remained stable and target joints modestly decreased, suggesting that bleeding outcomes alone may not fully reflect the evolving clinical burden in aging adults with haemophilia. TRIAL REGISTRATION: This study is registered in the Japan Registry of Clinical Trials (JRCT; https://jrct.mhlw.go.jp/latest-detail/jRCT1030190046).
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Five-Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study. — 科研速览 Science Skim